Rituximab plus 70% cyclophosphamide, doxorubicin, vincristine and prednisone for Japanese patients with diffuse large B-cell lymphoma aged 70 years and older.

Publisher: Taylor & Francis Country of Publication: United States NLM ID: 9007422 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1029-2403 (Electronic) Linking ISSN: 10268022 NLM ISO Abbreviation: Leuk Lymphoma Subsets: MEDLINE

Publication: [Philadelphia, PA] : Taylor & Francis
Original Publication: Chur ; New York : London, UK : Harwood Academic Publishers ; Distributed by STBS, 1989-

Antineoplastic Combined Chemotherapy Protocols/*therapeutic use ; Lymphoma, Large B-Cell, Diffuse/*drug therapy; Aged ; Aged, 80 and over ; Antibodies, Monoclonal, Murine-Derived/administration & dosage ; Antibodies, Monoclonal, Murine-Derived/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Asian People ; Cyclophosphamide/administration & dosage ; Cyclophosphamide/adverse effects ; Disease-Free Survival ; Doxorubicin/administration & dosage ; Doxorubicin/adverse effects ; Drug Administration Schedule ; Female ; Humans ; Japan ; Kaplan-Meier Estimate ; Leukopenia/chemically induced ; Lymphoma, Large B-Cell, Diffuse/ethnology ; Male ; Retrospective Studies ; Rituximab ; Thrombocytopenia/chemically induced ; Treatment Outcome ; Vincristine/administration & dosage ; Vincristine/adverse effects

In the rituximab era, several large studies have suggested that full-dose rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) might be the best treatment for patients with diffuse large B-cell lymphoma (DLBCL) aged 60 years and older. However, it remains unclear whether this is also the case for those aged 70 years and older. Previously untreated patients with DLBCL aged 70 years and older (elderly) were treated with R-70%CHOP, and patients younger than 70 years (younger) were treated with full-dose R-CHOP every 3 weeks, for a total of 6-8 cycles. Complete remission (CR) rates in elderly versus younger patients were 75 vs. 78% (p = 0.7), respectively. The 3-year overall survival, event-free survival and progression-free survival of elderly versus younger patients were 58 vs. 78% (p < 0.05), 45 vs. 70% (p < 0.05) and 64 vs. 72% (p = 0.43), respectively. Severe adverse events were more frequent in the elderly, even with the dose reduction in that age group. Three-year PFS with R-70%CHOP for patients aged 70 years and older was not significantly worse than that with full-dose R-CHOP for younger patients, suggesting that R-70% CHOP might be a reasonable choice for patients with DLBCL aged 70 years and older, especially for those with comorbidities.

0 (Antibodies, Monoclonal, Murine-Derived)
4F4X42SYQ6 (Rituximab)
5J49Q6B70F (Vincristine)
80168379AG (Doxorubicin)
8N3DW7272P (Cyclophosphamide)

Date Created: 20110826 Date Completed: 20120622 Latest Revision: 20221207

20250114

10.3109/10428194.2011.600486

21864040